Company Profile

KDAC Therapeutics Inc
Profile last edited on: 2/4/2020      CAGE: 7F2K2      UEI: MYM7MJ29ZZS3

Business Identifier: Death, apoptosis, and cell cycle arrest in cancer cells.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

400 Technology Square 10th Floor
Cambridge, MA 02139
   (617) 330-7000
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

KDAc Therapeutics is a biotechnology company anchored in technologies licensed from the Broad Institute of MIT and Harvard that are designed to translate discoveries in lysine acetylation and epigenetic regulation into novel treatments for cancer patients. In Summer 2019, OnKure, Inc. - discovery and development of selective histone deacetylase inhibitors - entered into an exclusive license and option agreement with KDAc Therapeutics, Inc. to support continued development of KDAc’s selective histone deacetylase 3 (HDAC3) inhibitor program. The collaboration focuses on continued advancement of KDAc’s lead candidate, KDAc-0001 (or OKI-422) --- Histone deacetylase (HDAC) inhibitors in a class of anti-cancer agents that play important roles in epigenetic and non-histone protein regulation, including death, apoptosis, and cell cycle arrest in cancer cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $225,000
Project Title: Selective HDAC3 Inhibitors as a Novel Therapy for Drug Addiction
2016 1 NIH $379,712
Project Title: Small Molecule Selective Hdac3 Inhibitors as a Novel Therapy for Ptsd

Key People / Management

  Edward Holson -- Founder, Director and CSO

  David Neafus -- CFO at KDAC Therapeutics